无码影视中文高清_亚洲天堂光棍影院_欧美激情欧美激情在线五月_国产精品日韩免费观看_一级黄色毛片成人影院_六月综合激情_亚洲av无码区国产乱码粉嫩_无遮挡免费视频_97操射操射人人色_可以免费观看的黄色完整版网站视频

掃碼關(guān)注公眾號           掃碼咨詢技術(shù)支持           掃碼咨詢技術(shù)服務(wù)
  
客服熱線:400-901-9800  客服QQ:4009019800  技術(shù)答疑  技術(shù)支持  質(zhì)量反饋  人才招聘  關(guān)于我們  聯(lián)系我們
好看的电视剧,手机推荐排行榜,小说网
首頁 > 產(chǎn)品中心 > 一抗 > 產(chǎn)品信息
Rabbit Anti-HIF-1 Alpha  antibody (bs-0737R)  
~~~促銷代碼KT202411~~~
訂購熱線:400-901-9800
訂購郵箱:sales@bioss.com.cn
訂購QQ:  400-901-9800
技術(shù)支持:techsupport@bioss.com.cn
說明書: 50ul  100ul  200ul
50ul/1180.00元
100ul/1980.00元
200ul/2800.00元
大包裝/詢價

產(chǎn)品編號 bs-0737R
英文名稱 Rabbit Anti-HIF-1 Alpha  antibody
中文名稱 缺氧誘導(dǎo)因子1α /低氧誘導(dǎo)因子-1抗體
別    名 ARNT interacting protein; ARNT-interacting protein; Basic helix loop helix PAS protein MOP1; Basic-helix-loop-helix-PAS protein MOP1; bHLHe78; Class E basic helix-loop-helix protein 78; HIF 1A; HIF 1alpha; HIF-1-alpha; HIF1 A; HIF1 Alpha; HIF1; HIF1-alpha; HIF1A; HIF1A_HUMAN; Hypoxia inducible factor 1 alpha; Hypoxia inducible factor 1 alpha isoform I.3; Hypoxia inducible factor 1 alpha subunit; Hypoxia inducible factor 1 alpha subunit basic helix loop helix transcription factor; Hypoxia inducible factor 1, alpha subunit (basic helix loop helix transcription factor); Hypoxia inducible factor1alpha; Hypoxia-inducible factor 1-alpha; Hypoxia-inducible factor-1a; Member of PAS protein 1; Member of PAS superfamily 1; Member of the PAS Superfamily 1; MOP 1; MOP1; PAS domain-containing protein 8; PASD 8; PASD8.  HIF-1a; HIF-1α;
Specific References  (76)     |     bs-0737R has been referenced in 76 publications.
[IF=18.027] Shikai Liu. et al. On-Demand Generation of Peroxynitrite from an Integrated Two-Dimensional System for Enhanced Tumor Therapy. ACS NANO. 2022;XXXX(XXX):XXX-XXX  IHC, WB ;  Mouse,Human.  
[IF=16.806] Jianting Yao. et al. Low-Intensity Focused Ultrasound-Responsive Ferrite-Encapsulated Nanoparticles for Atherosclerotic Plaque Neovascularization Theranostics. 2021 Aug 11  IF ;  Rabbit.  
[IF=14.919] Guan, Xin. et al. Nanoparticle-enhanced radiotherapy synergizes with PD-L1 blockade to limit post-surgical cancer recurrence and metastasis. NAT COMMUN. 2022 May;13(1):1-17  IF ;  Mouse.  
[IF=14.65] Liu, Hao-Yu. et al. Distinct B cell subsets in Peyer’s patches convey probiotic effects by Limosilactobacillus reuteri. Microbiome. 2021 Dec;9(1):1-18  FC ;  Mouse.  
[IF=14.588] Donglin Xia. et al. Au–Hemoglobin Loaded Platelet Alleviating Tumor Hypoxia and Enhancing the Radiotherapy Effect with Low-Dose X-ray. Acs Nano. 2020;14(11):15654–15668  IHC ;  Mouse.  
[IF=11.508] Rui Shao. et al. H3K36 methyltransferase NSD1 regulates chondrocyte differentiation for skeletal development and fracture repair. Bone Res. 2021 Jun;9(1):1-11  WB ;  Mouse.  
[IF=11.322] Chengzhong Xu. et al. Microenvironment responsive hypoxia-mimetic DFO composite hydrogel for on-demand neovascularization to promote tendon-to-bone healing. COMPOS PART B-ENG. 2023 Apr;:110726  IF ;  Human,Rat,Mouse.  
[IF=11.092] Juan Cen. et al. A Water-Soluble Quercetin Conjugate with Triple Targeting Exerts Neuron-Protective Effect on Cerebral Ischemia by Mitophagy Activation. ADV HEALTHC MATER. 2022 Sep;:2200817  WB, IHC ;  Rat, Human.  
[IF=10.652] Zhuo Liang. et al. Exosome derived from mesenchymal stem cells mediates hypoxia-specific BMP2 gene delivery and enhances bone regeneration. Chem Eng J. 2021 Oct;422:130084  IF ;  Rabbit.  
[IF=10.633] Qianqian Zhang. et al. Engineering a Synergistic Antioxidant Inhibition Nanoplatform to Enhance Oxidative Damage in Tumor Treatment. ACTA BIOMATER. 2023 Jan;:  IF ;  Human.  
[IF=10.317] Qi Sun. et al. Phototherapy and anti-GITR antibody-based therapy synergistically reinvigorate immunogenic cell death and reject established cancers. Biomaterials. 2021 Feb;269:120648  IHC ;  Mouse.  
[IF=9.918] Jie Hao. et al. Multifunctional miR181a nanoparticles promote highly efficient radiotherapy for rectal cancer. MATER TODAY ADV. 2022 Dec;16:100317  WB, IHC ;  Mouse.  
[IF=9.685] Chen, Yuyu. et al. Hnrnpk maintains chondrocytes survival and function during growth plate development via regulating Hif1α-glycolysis axis. CELL DEATH DIS. 2022 Sep;13(9):1-13  IF ;  Mouse.  
[IF=9.429] Zhou Daijun. et al. Multifunctional mesoporous silica-cerium oxide nanozymes facilitate miR129 delivery for high-quality healing of radiation-induced skin injury. J NANOBIOTECHNOL. 2022 Dec;20(1):1-16  WB ;  Human.  
[IF=8.128] Huaying Hou. et al. NIR-driven intracellular photocatalytic oxygen-supply on metallic molybdenum carbide@N-carbon for hypoxic tumor therapy. J Colloid Interf Sci. 2022 Feb;607:1  IHC ;  Mouse.  
[IF=8.071] Ze Zhang. et al. Oxygen sensors mediated HIF-1α accumulation and translocation: A pivotal mechanism of fine particles-exacerbated myocardial hypoxia injury. Environ Pollut. 2022 May;300:118937  WB,IF,IHC,IP ;  Mouse,Rat.  
[IF=7.675] Lei Lei. et al. Selenium Deficiency-Induced Oxidative Stress Causes Myocardial Injury in Calves by Activating Inflammation, Apoptosis, and Necroptosis. ANTIOXIDANTS-BASEL. 2023 Feb;12(2):229  WB ;  Cow.  
[IF=7.561] Ma Y. et al. Photobiomodulation Attenuates Neurotoxic Polarization of Macrophages by Inhibiting the Notch1-HIF-1α/NF-κB Signalling Pathway in Mice With Spinal Cord Injury.. Front Immunol. 2022 Mar;13:816952-816952  WB ;  Mouse.  
[IF=7.169] Cai, Sheng-lan. et al. CB2R agonist GW405833 alleviates acute liver failure in mice via inhibiting HIF-1α-mediated reprogramming of glycometabolism and macrophage proliferation. ACTA PHARMACOL SIN. 2023 Jan;:1-13  IF ;  Mouse.  
[IF=6.895] Fangmei Zhang. et al. X-ray-triggered NO-released Bi–SNO nanoparticles: all-in-one nano-radiosensitizer with photothermal/gas therapy for enhanced radiotherapy. 2020 Aug 31  IF ;  Human.  
[IF=6.843] Zhuowen Yang. et al. Ferrite-encapsulated nanoparticles with stable photothermal performance for multimodal imaging-guided atherosclerotic plaque neovascularization therapy. Biomater Sci-Uk. 2021 Jul;:  IHC ;  Rabbit.  
[IF=6.78] Na Du. et al. N-phenethyl-5-phenylpicolinamide alleviates inflammation in acute lung injury by inhibiting HIF-1α/glycolysis/ASIC1a pathway. LIFE SCI. 2022 Nov;309:120987  WB, IF ;  Mouse, Rat.  
[IF=6.633] Limin Liu. et al. Downregulation of fatty acid oxidation led by Hilpda increases G2/M arrest/delay-induced kidney fibrosis. BBA-MOL BASIS DIS. 2023 Jun;1869:166701  WB ;  Human,Mouse.  
[IF=6.389] Weixing Wang. et al. Oriented Fibers Cooperate with DFO to Prevent Tendon Adhesions by Improving the Repair Microenvironment. ADV MATER INTERFACES. 2023 Apr;:2300054  IF ;  Rat,Human,Mouse.  
[IF=6.244] Sun Q. et al. PKM2 Is the Target of a Multi-Herb-Combined Decoction During the Inhibition of Gastric Cancer Progression.. Front Oncol. 2021 Dec;11:767116-767116  WB ;  Human.  
[IF=6.183] Renjie Luo. et al. An Albumin-binding Dimeric Prodrug Nanoparticle with Long Blood Circulation and Light-triggered Drug Release for Chemo-photodynamic Combination Therapy against Hypoxia-induced Metastasis of Lung Cancer. 2021 Mar 26  IHC ;  Mouse.  
[IF=6.1] Tuling Li. et al. Inhibitory effect of miR-138-5p on choroidal fibrosis in lens-induced myopia guinea pigs via suppressing the HIF-1α signaling pathway. BIOCHEM PHARMACOL. 2023 May;211:115517  WB ;  Guinea pig.  
[IF=5.988] Dongfang Lv. et al. Mailuoshutong pill for varicocele-associated male infertility-Phytochemical characterisation and multitarget mechanism.. FRONT PHARMACOL. 2022 Sep;13:961011-961011  WB ;  Rat.  
[IF=5.923] Ayaka Ito. et al. Elevation of Chemosensitivity of Lung Adenocarcinoma A549 Spheroid Cells by Claudin-2 Knockdown through Activation of Glucose Transport and Inhibition of Nrf2 Signal. Int J Mol Sci. 2021 Jan;22(12):6582  WB ;  Human.  
[IF=5.88] Rui X et al. Imperative and effective reversion of synovial hyperplasia and cartilage destruction in rheumatoid arthritis through multiple synergistic effects of O2 and Ca2+. Mater Sci Eng C Mater Biol Appl.2020 Sep;114:111058.  IHC ;  Rat.  
研究領(lǐng)域 腫瘤  細(xì)胞生物  神經(jīng)生物學(xué)  信號轉(zhuǎn)導(dǎo)  細(xì)胞凋亡  
抗體來源 Rabbit
克隆類型 Polyclonal
交叉反應(yīng) Human,Rat (predicted: Mouse,Rabbit,Pig,Cow,Dog)
產(chǎn)品應(yīng)用 WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,Flow-Cyt=1μg/Test,ICC/IF=1:100,IF=1:100-500,ELISA=1:5000-10000
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
理論分子量 92kDa
細(xì)胞定位 細(xì)胞核 細(xì)胞漿 
性    狀 Liquid
濃    度 1mg/ml
免 疫 原 KLH conjugated synthetic peptide derived from middle of human HIF-1 Alpha: 341-450/826 
亞    型 IgG
純化方法 affinity purified by Protein A
緩 沖 液 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
保存條件 Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.
注意事項 This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
PubMed PubMed
產(chǎn)品介紹 Hypoxia-inducible factor-1 (HIF1) is a transcription factor found in mammalian cells cultured under reduced oxygen tension that plays an essential role in cellular and systemic homeostatic responses to hypoxia. HIF1 is a heterodimer composed of an alpha subunit and a beta subunit. The beta subunit has been identified as the aryl hydrocarbon receptor nuclear translocator(ARNT). This gene encodes the alpha subunit of HIF-1. Overexpression of a natural antisense transcript (aHIF) of this gene has been shown to be associated with nonpapillary renal carcinomas. Two alternative transcripts encoding different isoforms have been identified.

Function:
Functions as a master transcriptional regulator of theadaptive response to hypoxia. Under hypoxic conditions activatesthe transcription of over 40 genes, including, erythropoietin,glucose transporters, glycolytic enzymes, vascular endothelialgrowth factor, and other genes whose protein products increaseoxygen delivery or facilitate metabolic adaptation to hypoxia.Plays an essential role in embryonic vascularization, tumorangiogenesis and pathophysiology of ischemic disease. Binds to coreDNA sequence 5'-[AG]CGTG-3' within the hypoxia response element(HRE) of target gene promoters. Activation requires recruitment oftranscriptional coactivators such as CREBPB and EP300. Activity isenhanced by interaction with both, NCOA1 or NCOA2. Interaction withredox regulatory protein APEX seems to activate CTAD andpotentiates activation by NCOA1 and CREBBP.

Subunit:
Interacts with COPS5 subunit of COP9 signalosome complex,leading to the regulation of its stability. Interacts with TSGA10(By similarity). Efficient DNA binding requires heterodimerizationof an alpha and a beta/ARNT subunit. Binds to the TAZ-type 1domains of CREBBP and EP300. Interacts with NCOA1, NCOA2, APEX andHSP90. Interacts with VHL which docks HFA1 to the E3 ubiquitinligase complex for subsequent destruction. Interaction, via the ODDdomain, with the beta domain of VHLL, protects HIF1A fromdestruction by competing against the destructive targetinginitiated by VHL.

Subcellular Location:
Cytoplasm. Nucleus.

Tissue Specificity:
Expressed in most tissues with highest levels in kidney and heart. Overexpressed in the majority of common human cancers and their metastases, due to the presence of intratumoral hypoxia and as a result of mutations in genes encoding oncoproteins and tumor suppressors.

Post-translational modifications:
In normoxia, is hydroxylated on Pro-402 and Pro-564 in theoxygen-dependent degradation domain (ODD) by EGLN1/PHD1 andEGLN2/PHD2. EGLN3/PHD3 has also been shown to hydroxylate Pro-564.The hydroxylated prolines promote interaction with VHL, initiatingrapid ubiquitination and subsequent proteasomal degradation. Underhypoxia, proline hydroxylation is impaired and ubiquitination isattenuated, resulting in stabilization.
In normoxia, is hydroxylated on Asn-803 by HIF1AN, thusabrogating interaction with CREBBP and EP300 and preventingtranscriptional activation.
S-nitrosylation of Cys-800 may be responsible for increasedrecruitment of p300 coactivator necessary for transcriptionalactivity of HIF-1 complex.
Acetylation of Lys-532 by ARD1 increases interaction with VHLand stimulates subsequent proteasomal degradation.
Requires phosphorylation for DNA-binding.

Similarity:
Contains 1 basic helix-loop-helix (bHLH) domain.
Contains 1 PAC (PAS-associated C-terminal) domain.
Contains 2 PAS (PER-ARNT-SIM) domains.

SWISS:
Q16665

Gene ID:
3091

Database links:

Entrez Gene: 3091 Human

Entrez Gene: 15251 Mouse

Omim: 603348 Human

SwissProt: Q16665 Human

SwissProt: Q61221 Mouse

Unigene: 597216 Human

Unigene: 3879 Mouse

Unigene: 446610 Mouse




缺氧誘導(dǎo)因子1α不僅對于機(jī)體在缺氧條件下維持正常的生理功能具有特別重要的意義,并在腫瘤的生長以及神經(jīng)細(xì)胞凋亡等病理過程中起重要作用. HIF1 alpha能調(diào)節(jié)許多下游基因的表達(dá)水平.
哺乳動物細(xì)胞在低氧壓力條件下出現(xiàn)HIF。HIF是一種轉(zhuǎn)錄因子,對細(xì)胞的缺氧起穩(wěn)定作用。
產(chǎn)品圖片
25 ug total protein per lane of various lysates (see on figure) probed with HIF-1 Alpha polyclonal antibody, unconjugated (bs-0737R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
50 ng RHHIF-1 Alpha-Trx-His protein (bs-42326P) per lane probed with HIF-1 Alpha polyclonal antibody respectively, unconjugated (bs-0737R) at 1:1000 dilution and 4°C overnight incubation. Followed by corresponding conjugated secondary antibody incubation at r.t. for 60 min.
Tissue/cell: human cervical carcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-HIF-1-Alpha Polyclonal Antibody, Unconjugated(bs-0737R) 1:300, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Tissue/cell: rat lung tissue(Smoking); 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-HIF-1-Alpha Polyclonal Antibody, Unconjugated(bs-0737R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
Hela cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (HIF-1 Alpha) polyclonal Antibody, Unconjugated (bs-0737R) 1:100, 90 minutes at 37°C; followed by a conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei.
Hela cell; 4% Paraformaldehyde-fixed; Triton X-100 at room temperature for 20 min; Blocking buffer (normal goat serum, C-0005) at 37°C for 20 min; Antibody incubation with (HIF-1 Alpha) polyclonal Antibody, Unconjugated (bs-0737R) 1:100, 90 minutes at 37°C; followed by a conjugated Goat Anti-Rabbit IgG antibody at 37°C for 90 minutes, DAPI (blue, C02-04002) was used to stain the cell nuclei.
Blank control (blue line): Hela (blue). Primary Antibody (green line): Rabbit Anti- HIF-1 Alpha antibody (bs-0737R) Dilution: 1μg /10^6 cells; Isotype Control Antibody (orange line): Rabbit IgG . Secondary Antibody (white blue line): Goat anti-rabbit IgG-FITC Dilution: 1μg /test. Protocol The cells were fixed with 80% methanol (5 min at -20℃) and then permeabilized with 0.1% PBS-Tween for 20 min at room temperature. Cells stained with Primary Antibody for 30 min at room temperature. The cells were then incubated in 1 X PBS/2%BSA/10% goat serum to block non-specific protein-protein interactions followed by the antibody for 15 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
Blank control:Mouse spleen. Primary Antibody (green line): Rabbit Anti-HIF-1 Alpha antibody (bs-0737R) Dilution: 2μg /10^6 cells; Isotype Control Antibody (orange line): Rabbit IgG . Secondary Antibody : Goat anti-rabbit IgG-FITC Dilution: 1μg /test. Protocol The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 90% ice-cold methanol for 20 min at -20℃. The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
版權(quán)所有 2004-2026 xiaowangchong.cn 北京博奧森生物技術(shù)有限公司
通過國際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書編號: 00124Q34771R2M/1100
通過國際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書編號: CQC24QY10047R0M/1100
京ICP備05066980號-1         京公網(wǎng)安備110107000727號